Investigation Commenced into Fairness of Revance Therapeutics Acquisition by Crown Laboratories
New York, NY – February 3, 2025
Levi & Korsinsky, LLP, a leading securities law firm, has announced the commencement of an investigation into the fairness of the acquisition of Revance Therapeutics Inc (RVNC) by Crown Laboratories, Inc. (Crown).
Background
Revance Therapeutics, a biotechnology company based in New Jersey, specializes in the development of innovative therapies for aesthetic and neurotherapeutics markets. The Company’s most notable product is DaxibotulinumtoxinA for Injectable Use, a long-acting formulation of botulinum toxin type A, which is used for various aesthetic indications. In August 2024, it was announced that Crown Laboratories would acquire Revance in a cash and stock deal valued at approximately $1.1 billion.
Investigation Details
The investigation focuses on whether the consideration paid by Crown undervalues Revance shares. The law firm is urging Revance stockholders to contact them if they wish to discuss their rights and potential remedies. Levi & Korsinsky is committed to ensuring that all investors receive the compensation they are entitled to.
Impact on Individual Investors
If you own Revance stock purchased prior to August 11, 2024, you may be affected by this investigation. As a stockholder, you have certain options and protections under the law. You may be entitled to compensation if it is determined that the acquisition was not fair to Revance stockholders. Levi & Korsinsky, LLP urges you to contact them to discuss your rights and potential remedies.
Impact on the World
The outcome of this investigation could have significant implications for the biotech industry and the M&A market. If it is determined that Revance stockholders were not fairly compensated, it could potentially lead to increased scrutiny of similar transactions in the future. Additionally, it could potentially discourage companies from pursuing acquisitions if they fear facing similar investigations.
Conclusion
Levi & Korsinsky, LLP’s investigation into the fairness of the acquisition of Revance Therapeutics by Crown Laboratories is an important development for both individual investors and the biotech industry as a whole. As a stockholder, you have the right to seek compensation if you believe you were not fairly compensated for your shares. The investigation’s outcome could potentially set a precedent for future M&A transactions in the industry. If you have any questions or wish to discuss your rights, contact Levi & Korsinsky, LLP.
- Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance Therapeutics Inc (RVNC) by Crown Laboratories, Inc. (Crown).
- The investigation focuses on whether the consideration paid by Crown undervalues Revance shares.
- Anyone who owns Revance stock purchased prior to August 11, 2024, may be affected and encouraged to contact Levi & Korsinsky, LLP to discuss their rights and potential remedies.
- The outcome of this investigation could have significant implications for the biotech industry and the M&A market.
